Brain and Central Nervous System Tumors Clinical Trial
Official title:
Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to
the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving CT-322 together with irinotecan may kill more tumor cells.
PURPOSE: This phase 2 trial is studying the side effects, tolerability, and efficacy of
CT-322 when given alone and in combination with irinotecan to patients with glioblastoma
multiforme.
Status | Active, not recruiting |
Enrollment | 72 |
Est. completion date | December 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS - Histologically confirmed diagnosis of recurrent/progressive GBM presenting in first, second, or third relapse (progression following anti-cancer therapy other than surgery) - Bidimensionally measurable recurrent or residual primary disease on contrast-enhanced MRI PATIENT CHARACTERISTICS Age: • 18 and over Hematopoietic: - ANC = 1,500/mL - Platelets = 100,000/mL - Hemoglobin = 9.0g/dL Hepatic: - AST and ALT = 1.5 x ULN - Bilirubin = 1.5 x ULN Coagulation: • INR < 1.5 or PT within normal limits; and PTT within normal limits Renal: Creatinine = 1.5 x ULN; Urine protein/creatinine ratio = 1 Cardiovascular - 2-dimensional echocardiogram or cardiac multigated acquisition (MUGA) scan demonstrating left ventricular ejection fraction within the institutional normal range. - No coronary artery bypass graft, angioplasty, vascular stenting, myocardial infarction, unstable angina, congestive heart failure within the preceding 12 months. - No thrombotic or embolic cerebrovascular accident, including transient ischemic attacks within the past 12 months and no conditions that would not permit the safe discontinuation of specified anti-platelet medications - No intraparenchymal CNS hemorrhage, except for Grade 1 intraparenchymal hemorrhage in the immediate post-operative period or Grade 1 intraparenchymal hemorrhage that has been stable or improved Immunologic: • Not known to have human immunodeficiency virus infection (HIV) or active hepatitis B or C virus infection Other: - Negative pregnancy test within 72 hours prior to drug administration - Not pregnant or breast feeding - Fertile patients must agree to use effective methods of birth control and must agree to do so until at least 4 weeks after the last dose of drug administration - No serious non-healing wound, ulcer or bone fracture or recent significant traumatic injury (within 4 weeks) - Have ability to understand and sign an informed consent document - Be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures - No other malignancy within the past 3 years, except for basal cell skin cancer, cervical carcinoma in situ, or other primary malignancy that is not currently clinically significant or does not require active intervention - No prior grade 3 or greater toxicity to irinotecan - No other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that could increase the risks associated with study participation or study drug administration or could interfere with the interpretation of the study results and would make the patient inappropriate for study entry PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - At least 4 weeks between prior biological or immunotherapy and recovered Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy and recovered (6 weeks for nitrosoureas), unless there is unequivocal evidence of tumor progression Radiotherapy: • At least 12 weeks from completion of standard, daily radiotherapy and recovered, unless any of the following occurs: - New area of enhancement on MRI that is outside the radiotherapy field - Biopsy-proven recurrent tumor - Radiographic evidence of progressive tumor on 2 consecutive scans taken = 4 weeks apart Surgery - At least 4 weeks since major surgery, open biopsy or significant traumatic injury and recovered - At least 1 week since other prior biopsy Other: - Not concurrently enrolled in another therapeutic clinical trial involving ongoing therapy - No prior treatment with VEGF or VEGFR inhibitors or vascular targeting/disrupting agents - No prior CT-322 therapy - No prior failure of irinotecan therapy - No prior treatment with stereotactic radiosurgery, brachytherapy, or a surgically created resection cavity to support other anatomically localized therapies - No severe or uncontrolled medical disease (uncontrolled diabetes, hypertension, serious infection > CTCAE grade 2, significant bleeding or platelet dysfunction, gastrointestinal bleed) |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | University of Virgina | Charlottesville | Virginia |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Duke University Medical Center | Durham | North Carolina |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | University of California, San Diego | La Jolla | California |
United States | University of Kentucky | Lexington | Kentucky |
United States | University of Wisconsin Hospital | Madison | Wisconsin |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | SUNY Upstate Medical University | Syracuse | New York |
Lead Sponsor | Collaborator |
---|---|
Adnexus, A Bristol-Myers Squibb R&D Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of CT-322 when administered alone or in combination with irinotecan hydrochloride (Part 1) | 15 ± 5 days post the last dose of study drug | Yes | |
Primary | Progression-free survival at 6 months (Part 2) | Measured upon initiation of cycles 2, 3, 5, 7, 9, 11, and end of study | No | |
Secondary | To assess the plasma pharmacokinetics of CT-322 (Cmax, Tmax, AUC, T-HALF) derived from plasma concentration vs time for CT-322 given alone and in combination with irinotecan | Part 1: cycle 1, days 1-3, day 5 or 6, days 8, 15, and 22; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. Part 2: cycle 1, days 1, 8, 15, and 22; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. | No | |
Secondary | To assess the presence of anti CT-322 antibodies | Part 1: cycle 1, days 1 and 15; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. Part 2: cycle 1, days 1 and 15; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. | No | |
Secondary | To assess the biological activity of CT-322 as measured by plasma biological markers and neuroimaging | Part 1: cycle 1, days 1, 2, 8, 15 and 22; cycles 2-4, 6, 9, and 12, day 1; EOS visit. Part 2: cycle 1, days 1, 8, 15 and 22; cycles 2-4, 6, 9, and 12 EOS visit. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 |